Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastasesElizabeth Dudnik, Nir Peled, Shlomit Yust‐Katz et al.|Lung Cancer|2016Cited by 136
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Mor Moskovitz et al.|Lung Cancer|2017Cited by 104
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerDaniel A. Goldstein, Alona Zer, Nikita Patel et al.|JNCI Journal of the National Cancer Institute|2017Cited by 102
Common Sense Oncology: outcomes that matterChristopher M. Booth, Bishal Gyawali, Elizabeth A. Eisenhauer et al.|The Lancet Oncology|2023Cited by 101